4Q Revenues: $8.2 million (earnings were $2.7 million in 4Q11)
4Q Loss: $58.6 million (loss of $44.5 million in 4Q11)
FY Revenues: $26.2 million (earnings were $5.4 million FY11)
FY Loss: $150.1 million (loss of $154.8 million FY11)
Comments: Esbriet (pirfenidone) revenue in the quarter was $8.2 million, up 204%. Results in the quarter included the effect of the approximate 11% German price decrease of Esbriet, which became effective September 15, 2012. Esbriet was approved in Canada October 1, 2012 for the treatment of mild to moderate IPF and became commercially available on January 2, 2013.